Thu, Mar 8, 9:10 AM, Zacks
Quest Diagnostics Long-Term View Solid, Reimbursement a Woe
Quest Diagnostics (DGX) upgraded long-term guidance based on its new and extended two-point strategy looks promising. However, it expresses resentment against the recent PAMA-related CMS proposal.
Tue, Feb 13, 6:17 AM, Zacks
Here's Why You Should Sweep Up Quest Diagnostics Right Now
Quest Diagnostics (DGX) latest acquisitions boost investors confidence.